What does Breztri Aerosphere prescribing information say it’s used for?
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) is prescribed for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It is not indicated for asthma or for acute deterioration of COPD symptoms (such as sudden worsening that needs immediate rescue treatment).
How is Breztri Aerosphere taken (dose, frequency, device)?
The prescribing information specifies that Breztri Aerosphere is used as an inhalation via an inhaler device. Dosing is typically scheduled twice daily (morning and evening), and patients should follow the dosing instructions provided with the specific inhaler and prescription label.
If a patient misses a dose, the prescribing information instructs them to take the next dose at the regular time rather than taking extra doses.
Who should not use Breztri (key contraindications)?
Breztri Aerosphere prescribing information includes contraindications and warnings related to:
- Allergy to any components of the product.
- Use in situations where immediate relief is needed for acute bronchospasm (patients should use an appropriate rescue medication instead).
What important warnings are in the prescribing information?
Breztri’s prescribing information includes boxed warnings and major safety warnings associated with its component classes, including:
- Serious asthma-related risks (because the product is not for asthma, the labeling emphasizes risks of inhaled corticosteroids in asthma populations when used incorrectly).
- Pneumonia risk in COPD patients receiving inhaled corticosteroids.
- Cardiovascular effects and other risks related to long-acting beta agonists (LABA), including potential effects on heart rate and rhythm.
- Potential worsening of existing conditions related to anticholinergic activity (from glycopyrrolate).
- Decreased bone mineral density and other steroid-related systemic effects at higher exposures.
- Effects on blood sugar and adrenal suppression risk with corticosteroid use.
- Risks of hypokalemia (low potassium), which can be associated with beta agonists.
What side effects are commonly reported?
The prescribing information lists adverse reactions for COPD patients on Breztri, including symptoms consistent with inhaled therapy and COPD comorbidities. Patients and clinicians often focus on:
- Pneumonia and lower respiratory infections
- Oral and throat effects typical of inhaled corticosteroids (such as oral thrush)
- COPD exacerbations
- Headache and other nonspecific effects
- Possible cardiovascular or tremor-related effects (consistent with LABA class effects)
What drug interactions does the prescribing information flag?
The prescribing information highlights clinically important interactions, especially for:
- Other LABA-containing medicines (risk of additive beta agonist effects)
- Certain CYP450 inhibitors that can affect formoterol metabolism
- Hypokalemia-associated medicines (for example, other agents that lower potassium), which can increase risk when combined with beta agonists
- Anticholinergic medicines (additive anticholinergic effects)
Can Breztri be used with rescue inhalers?
Breztri Aerosphere is for maintenance COPD control, so the prescribing information directs patients not to use it as a rescue medication for sudden breathing problems. Patients generally should have a separate rescue inhaler for acute symptoms, as prescribed.
Is Breztri Aerosphere the same as budesonide/formoterol or other combo inhalers?
Breztri is a triple therapy inhaler combining:
- An inhaled corticosteroid (budesonide)
- A long-acting muscarinic antagonist (glycopyrrolate)
- A long-acting beta agonist (formoterol fumarate)
That combination is different from two-drug inhalers (for example, inhaled steroid/LABA only, or LAMA/LABA only) and from single-agent inhalers.
Where can I find the official prescribing information text?
You can look up detailed Breztri prescribing information and label availability through DrugPatentWatch.com: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/